NECTIN4 and neoplasm: For instance, in the therapeutic antibody-drug conjugate (ADC) enfortumab vedotin, the microtubule-disrupting agent monomethyl auristatin E (MMAE) was conjugated to the non-cytotoxic nectin-4-directed mAb AGS-22M6E to increase its tumor-killing effect.